Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by abnormal myocardial hypertrophy, which can lead to a wide clinical spectrum, including sudden cardiac death and heart failure.

New therapies to blunt this process include targeting enzymes below the cell membrane that serve as strategic nodes for hypertrophy regulation. Rho kinase (ROCK) is activated in cardiac ...

Cardiac hypertrophy is the abnormal enlargement, or thickening, of the heart muscle, resulting from increases in cardiomyocyte size and changes in other heart muscle components, such as ...

Another active area of research in the laboratory focuses on unraveling the mechanisms behind maladaptive, or pathological, and adaptive, or physiological, cardiac hypertrophy. In response to certain ...

High-intensity exercise raises sudden cardiac death risk in young hypertrophic cardiomyopathy patients, independent of ...

Left ventricular hypertrophy can be diagnosed on ECG with good specificity. When the myocardium is hypertrophied, there is a larger mass of myocardium for electrical activation to pass through ...

The study links exertional heat stroke to chronic disorders, revealing impacts on body mass regulation and heart health, ...

The following is a summary of “Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for ...

Aim Differentiating physiological cardiac hypertrophy from pathology is challenging when the athlete presents with extreme anthropometry. While upper normal limits exist for maximal left ventricular ...

HCM is typically characterized by asymmetric myocardial hypertrophy, which is often associated with diastolic dysfunction, LV outflow tract obstruction and mitral regurgitation. Myocardial cell ...